Alnylam Pharmaceuticals, Inc.
DE ˙ XTRA ˙ US02043Q1076
260,50 € ↑8,70 (3,46%)
2026-06-04
DEL PRIS
SecurityDE:DUL / Alnylam Pharmaceuticals, Inc.
InstitutionKestra Advisory Services, LLC
Latest Disclosed Ownership1,184 shares
Latest Disclosed Value $ 391,750
Kestra Advisory Services, LLC reports 36.03% decrease in ownership of DUL / Alnylam Pharmaceuticals, Inc.

On April 30, 2026 - Kestra Advisory Services, LLC filed a 13F-HR form disclosing ownership of 1,184 shares of Alnylam Pharmaceuticals, Inc. (DE:DUL) valued at $338,269 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 13, 2026 disclosing 1,851 shares of Alnylam Pharmaceuticals, Inc.. This represents a change in shares of -36.03% during the quarter. The current value of the position is $308,432 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-04-30 2026-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,184 -667 -36.03 392 -46.87 0.0015
2026-02-13 2025-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,851 206 12.52 736 -1.87 0.0030
2025-11-14 2025-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,645 561 51.75 750 112.46 0.0034
2025-08-15 2025-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,084 126 13.15 353 36.82 0.0017
2025-05-14 2025-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 958 -629 -39.63 259 -30.83 0.0013
2025-02-10 2024-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,587 284 21.80 373 4.19 0.0020
2024-11-13 2024-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,303 -88 -6.33 358 5.92 0.0020
2024-08-14 2024-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,391 32 2.35 338 66.50 0.0019
2024-05-15 2024-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,359 91 7.18 203 -16.12 0.0014
2024-02-14 2023-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,268 1,268 243 0.0020
2023-08-11 2023-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 0 -1,066 -100.00 0 -100.00
2023-05-12 2023-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,066 -1,272 -54.41 214 -61.62 0.0023
2023-01-31 2022-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 2,338 721 44.59 556 0.0049
2022-11-01 2022-09-30 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 1,617 201 14.19 0 0.0035
2022-11-01 2022-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,617 201 324 0.0035
2022-08-12 2022-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,416 77 5.75 0 0.0021
2022-07-20 2022-03-31 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 1,339 74 5.85 0 -100.00 0.0023
2022-04-26 2022-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,339 74 219 0.0023
2022-07-25 2021-12-31 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 1,265 -1,435 -53.15 0 -100.00 0.0022
2022-01-20 2021-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,265 -1,435 215 0.0022
2022-07-25 2021-09-30 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 2,700 2,700 1 0.0051
2021-10-19 2021-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 2,700 2,700 510 0.0051
2022-07-28 2020-12-31 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 0 -67 -100.00 0 -100.00
2021-01-20 2020-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 0 -67 0
2022-07-29 2020-09-30 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 67 67 639,000 0.0119
2020-11-12 2020-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 67 67 639 0.0119
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.